Cerylid biosciences , australia
Cerylid Biosciences and Anadys Pharmaceuticals Announce Anti-Infective Drug Discovery Partnership
San Diego, CA, June 06, 2002 -Cerylid Biosciences Limited (Cerylid) and Anadys Pharmaceuticals, Inc.
(Anadys) announced today a strategic partnership for the discovery of novel anti-infective compounds.
This partnership will utilize Anadys' uHTS-ATLAS™ technology to screen Cerylid's world leading
collection of natural products against key Anadys targets.
Under the terms of the collaboration, Anadys will gain access to Cerylid's extensive library of unique
natural products samples derived predominantly from organisms of Australian origin. Anadys will
screen the samples against important undisclosed anti-infective targets using its uHTS-ATLAS™ ultra
high-throughput screening methodologies. Cerylid will then use its expertise in natural products
chemistry to identify biologically active small molecules in extracts that show positive results in the
screens. Anadys will have responsibility for advancing compounds through lead optimization, as well as
"We are very pleased to gain access to Cerylid's industry-leading capabilities in natural products drug
discovery," said Dr. Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Anadys. "We believe that
Cerylid has developed the world's largest and most chemically diverse natural products library, as well
as unique techniques for the identification of novel compounds. We expect this to be an effective
complement to the powerful screening techniques we have developed at Anadys and will facilitate our
efforts to discover new and powerful drugs."
"This drug discovery collaboration with Anadys is an ideal marriage of technologies. By combining our
library of natural product samples with Anadys' unique and powerful screening methodologies, there are
great prospects for the discovery of novel anti-infectives. We are delighted to join with Anadys in this
new partnership," said Dr. Jackie Fairley, CEO of Cerylid.
Anadys Pharmaceuticals, Inc. ("Anadys") is a new generation drug discovery company committed to
applying an integrated approach that combines biology and chemistry to develop new small molecule
therapeutics. The Company is committed to developing novel powerful antibiotics and medicines to treat
viral infections. To that end, Anadys has assembled and integrated a proprietary suite of technologies to
identify novel targets (using GATE™ and Riboproteomics™), screen them for small molecule effectors
(uHTS-ATLAS™ and SCAN™), and develop clinical candidates using its considerable capabilities in
high-output medicinal chemistry. Anadys has a specific capability to exploit RNA-related targets and
novel chemistries to find new medicines using its leadership position in Riboproteomics™. RNA-related
targets have been validated with the approval of drugs such as neomycin, Zyvox®, and Zithromax®.
Anadys intends to harness this integrated suite of technologies to propel a strong and continual pipeline
Beneath the Surf Author: Julia Owen Synopsis It’s summer, 1975 and 15 year-old Yasmin is on holiday with her mum and brother. The trio are staying in a bach and the only things on Yasmin’s mind are lying on the beach in her new bikini, working on her tan and meeting cute guys. When Yasmin meets Gail, a 17 year-old surfie chic, her prayers are answered. Gail invites her to a
CENTRE NATIONAL POUR LA RECHERCHE SCIENTIFIQUE ET TECHNIQUE APPEL D’OFFRES OUVERT SUR OFFRES DE PRIX N°02/2011/CNRST/IMIST (SEANCE PUBLIQUE) RELATIF A La fourniture, l’installation et la mise en place de matériel informatique pour l’institut marocain de l’information scientifique et technique (IMIST) relevant du CNRST - EN LOT UNIQUE- Cahier des prescri